Enjoy complimentary customisation on priority with our Enterprise License!
The in-vitro toxicity testing market share is expected to increase by USD 5.18 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 10.09%.
This in-vitro toxicity testing market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers in-vitro toxicity testing market segmentation by end-user (pharmaceutical and biotechnology companies, academic and research institutions, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The in-vitro toxicity testing market report also offers information on several market vendors, including Abbott Laboratories, Agilent Technologies Inc., Aragen Life Sciences Pvt. Ltd., Bio Rad Laboratories Inc., BioIVT LLC, Catalent Inc., Charles River Laboratories International Inc., Creative Bioarray, Creative Biolabs, Eurofins Scientific SE, Evotec SE, Gentronix Ltd., InSphero AG, Laboratory Corp. of America Holdings, MB Research Labs, Merck KGaA, Promega Corp., SGS SA, Thermo Fisher Scientific Inc., and XENOMETRIX AG among others.
Download Report Sample to Unlock the IVTT Market Size for the Forecast Period and Other Important Statistics
The increasing use of in-vitro toxicity testing by companies to reduce drug failures is notably driving the in-vitro toxicity testing market growth, although factors such as limitations of preclinical studies may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the in-vitro toxicity testing industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key InVitro Toxicity Testing (IVTT) Market Driver
One of the key factors driving growth in the IVTT market is the increasing use of in-vitro toxicity testing by companies to reduce drug failures. The in-vitro toxicity testing of new compounds is essential, as it reveals the species, organ, and dose-specific toxic effects of drugs. Toxicity is one of the major factors that are responsible for the rejection of drugs in the last development phase. Lack of toxicity testing, which leads to drug failure or rejection, incurs high costs and significant time for companies. This is because they spend significant time and financial resources to discover molecules for drugs, which can have development-limiting liabilities at a later stage. Without in-vitro toxicity testing, companies also fail to understand the interaction of compounds with cells, tissues, and organs. The increasing use of tests by pharmaceutical and biotechnology companies to reduce drug failures and rejection is driving the growth of the global in-vitro toxicity testing market.
Key InVitro Toxicity Testing (IVTT) Market Trend
The advances in toxicology are an IVTT market trend that is expected to have a positive impact in the coming years. The field of toxicology is characterized by the advanced understanding of the human biological system and diseases at a molecular level while reducing the risk of human and animal studies. The adoption of techniques such as in-vitro and in-silico testing methods is increasing as a replacement for in-vivo methods as they involve experimentation on whole living organisms as opposed to dead organisms. The need to detect diseases at a molecular level and screen chemicals in the pharmaceutical industry to identify specific biological functionalities with minimal adverse effects has made the in-vivo method not beneficial. Thus, the in-vitro testing method is evolving due to advances in various technologies, such as cell culture technologies, cellular imaging technologies, and toxicogenomic. The advances in the field of toxicology are positively impacting the growth of the global invitro toxicity testing market.
Key InVitro Toxicity Testing (IVTT) Market Challenge
The limitations of preclinical studies will be a major challenge for the IVTT market during the forecast period. Preclinical studies yield proof of preliminary drug efficacy, which is required for the development process of a new drug and to check its toxicity, pharmacokinetics, and safety information to assess if it is ready for clinical trials. The lack of adequate assessment of risks and the development of risk mitigation strategies related to preclinical research, including data, documents, and conclusions, will lead to the failure of such preclinical studies and, hence, increase the cost incurred for such studies. Preclinical studies have practical limitations such as small experiments, and duration of drug administration, which increase the cost of conducting such studies. Therefore, the limitations of preclinical studies are affecting the growth of the market, as in-vitro toxicity testing cannot be carried out without implementing successful preclinical studies.
This in-vitro toxicity testing market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global in-vitro toxicity testing market as a part of the global life science tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the IVTT market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the in-vitro toxicity testing market encompasses successful business strategies deployed by the key vendors. The in-vitro toxicity testing market is fragmented and the vendors are deploying growth strategies such as technological innovations and mergers and acquisitions (M&A) to compete in the market.
abbott.com - The company offers in-vitro toxicity testing products such as ARCHITECT c4000, ARCHITECT c8000, and ARCHITECT c16000.
abbott.com - Under the established pharmaceuticals products segment, the company manufactures branded generic pharmaceuticals for established and emerging markets.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The IVTT market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the in-vitro toxicity testing market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
39% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for in-vitro toxicity testing in North America. Market growth in this region will be slower than the growth of the market in the European regions.
The demand for in-vitro toxicity testing is rising from the pharmaceutical and biotechnology vendors and the food and beverage companies located in the region. This will facilitate the in-vitro toxicity testing market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic in 2020 negatively impacted the economy of North America. The pandemic hampered the regional market to a certain extent. The outbreak affected several manufacturing processes and resulted in supply chain disruptions. However, the outbreak boosted the growth of the regional in-vitro toxicity testing market. The imposition of lockdowns in North America decreased the number of COVID-19 cases in the last quarter of 2020. Furthermore, the widespread vaccination programs are expected to boost the regional market growth in Q1 2021. Hence, the in-vitro toxicity testing market in North America is expected to grow during the forecast period.
To gain further insights on the market contribution of various segments Request PDF Sample
The in-vitro toxicity testing market share growth by the pharmaceutical and biotechnology companies segment will be significant during the forecast period. With increasing drug development in the biotechnology field, there is a surge in demand for in-vitro toxicity testing that uses microorganisms, cells, and biological molecules, as well as computer and mathematical models, to screen drugs at an early stage. Such models aid in generating verifiable predictions and test hypotheses, as well as in virtual experiments, while ensuring that drugs are safe for use. Thus, the rise in drug discovery and drug development is resulting in an increase in the demand for in-vitro toxicity testing from pharmaceutical and biotechnology companies.
This report provides an accurate prediction of the contribution of all the segments to the growth of the in-vitro toxicity testing market size and actionable market insights on post COVID-19 impact on each segment.
In-vitro Colorectal Cancer Screening Tests market - The market size has the potential to grow by USD 270.96 million during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 5.60%.
In-vitro Diagnostics market - The market share is projected to grow by USD 33.16 billion with a CAGR of 6.89% during the forecast period 2021 to 2026.
InVitro Toxicity Testing (IVTT) Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.09% |
Market growth 2022-2026 |
$ 5.18 billion |
Market structure |
Fragmented |
YoY growth (%) |
9.68 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key consumer countries |
US, Canada, Germany, UK, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, Agilent Technologies Inc., Aragen Life Sciences Pvt. Ltd., Bio Rad Laboratories Inc., BioIVT LLC, Catalent Inc., Charles River Laboratories International Inc., Creative Bioarray, Creative Biolabs, Eurofins Scientific SE, Evotec SE, Gentronix Ltd., InSphero AG, Laboratory Corp. of America Holdings, MB Research Labs, Merck KGaA, Promega Corp., SGS SA, Thermo Fisher Scientific Inc., and XENOMETRIX AG |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.